![fulcrumscientific/4,5,6,7-Tetrahydrothiazolo[5,4-c]pyridin-2-amine/97817-23-7](https://www.ebiomall.cn/images/lookchem/97817-23-7.jpg)
![fulcrumscientific/N-ETHYL-N-PYRIDIN-4-YLMETHYL-4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-BENZAMIDE/864759-43-3](https://www.ebiomall.cn/images/lookchem/864759-43-3.jpg)
DJ Fulcrum Therapeutics Names New Chief Scientific Officer
By Stephen Nakrosis
Fulcrum Therapeutics Inc. on Tuesday said it promoted Christopher Moxham to the role of chief scientific officer.
Dr. Moxham will succeed Owen Wallace, who will step down as chief scientific officer, effective Feb. 5, \"to pursue another opportunity,\" the company said, adding that Dr. Wallace was appointed to Fulcrum\'s Scientific Advisory Board.
Fulcrum said Dr. Moxham \"played a key role in the discovery of FTX-6058, its highly potent small molecule inhibitor of EED for the treatment of hemoglobinopathies, such as sickle cell disease and beta thalassemia.\"
The company said before joining the company in 2019, Dr. Moxham spent over 20 years in drug discovery primarily, at Eli Lilly and Co.
Fulcrum said it is \"a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases.\"
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
January 19, 2021 18:06 ET (23:06 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
2021年1月20日DJ Fulcrum Therapeutics Names New Chief Scientific Officer By Stephen Nakrosis Fulcrum Therapeutics Inc. on Tuesday said it promoted Christ...Fulcrum Therapeutics Names New Chief Scientific OfficerDJ Fulcrum Therapeutics Names New Chief Scientific Officer By Stephen Nakrosis Fulcrum Therapeutics Inc. on Tuesday said it promoted Christopher Moxham to the role of chief scientific officer.Fulcrum Therapeutics Names New Chief Scientific Officer
本文链接： http://fulcrumscientific.immuno-online.com/view-739589.html
